post-add

Articles for Regulatory

Alleged Irregularities: CBI Conducts Search At Rishikesh AIIMS

A CBI team under the direction of Deputy Superintendent of Police Rajeev Chandola is conducting the search. In April 2022, the CBI conducted raids at the AIIMS in Rishikesh and filed two separate cases against five individuals

Read More
USFDA Inspects Lupin's Pithampur Unit-2, Issues 10 Observations

On Thursday, Mumbai-based Lupin pharmaceuticals informed that the top regulatory body USFDA issued a Form-483 with 10 observations for its second manufacturing unit at Pithampur, Madhya Pradesh

Read More
Govt's Crackdown On 76 Pharma Companies & What It Symbolises

As per media reports, three companies' permission to manufacture specific products was also cancelled

Read More
Zydus Gets Final Approvals From USFDA To Market Generic Drugs

Zydus Lifesciences on Tuesday informed that it has received final approval for two drugs from the United States Food and Drug Administration (USFDA) including Doxepin Hydrochloride Capsules and Levothyroxine Sodium for Injection

Read More
Sanofi Gets Marketing Nod From CDSCO To Sell Its Diabetes Drug

Sanofi India on Monday informed that it has received marketing authorization for its diabetes drug Soliqua (in a pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO)

Read More
Indian Immunologicals Gets DCGI Approval For Measles-Rubella Vaccine

Measles is caused by a virus that lives in the nose and throat mucus of an infected person and spreads easily through breathing, coughing, and sneezing. There is no specific antiviral drug available to treat measles

Read More
Glenmark Gets USFDA Nod For First-in-human Study For Tumors, Lymphomas

Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals, the global pharmaceuticals company received acceptance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumours and lymphomas

Read More
DCGI Alerts States, UTs Against Raw Materials From Maya Chemtech, Supplier Of Marion Biotech

The Drug Controller General of India (DCGI), Rajeev Singh Raghuvanshi has issued a letter to the states and union territory licensing authorities against the usage of raw materials produced by Delhi based Maya Chemtech India that supplied the ingredients for the drugs at Marion Biotech which caused the death of 18 children in Uzbekistan

Read More

Subscribe to our newsletter to get updates on our latest news